A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
Public ClinicalTrials.gov record NCT07628049. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years
Study identification
- NCT ID
- NCT07628049
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 1,808 participants
Conditions and interventions
Interventions
- RSV/hMPV_V low dose vaccine Biological
- RSV/hMPV_V medium dose vaccine Biological
- RSV/hMPV_V high dose vaccine Biological
- RSV/hMPV_W low dose vaccine Biological
- RSV/hMPV_W medium dose vaccine Biological
- RSV/hMPV_W high dose vaccine Biological
- RSV/hMPV_X low dose vaccine Biological
- RSV/hMPV_X medium dose vaccine Biological
- RSV/hMPV_X high dose vaccine Biological
- hMPV_Y low dose vaccine Biological
- hMPV_Y medium dose vaccine Biological
- hMPV_Y high dose vaccine Biological
- hMPV_Z low dose vaccine Biological
- hMPV_Z medium dose vaccine Biological
- hMPV_Z high dose vaccine Biological
- Control vaccine Biological
- Placebo Combination Product
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 4, 2026
- Primary completion
- Apr 4, 2029
- Completion
- Apr 4, 2029
- Last update posted
- Jul 7, 2026
2026 – 2029
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Lenexa | Kansas | 66219 | Recruiting |
| GSK Investigational Site | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07628049, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07628049 live on ClinicalTrials.gov.